Advertisement

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Margaret Nieborowska-Skorska, Silvia Maifrede, Yashodhara Dasgupta, Katherine Sullivan, Sylwia Flis, Bac Viet Le, Martyna Solecka, Elizaveta A. Belyaeva, Lucia Kubovcakova, Morgan Nawrocki, Martin Kirschner, Huaqing Zhao, Josef T. Prchal, Katarzyna Piwocka, Alison R. Moliterno, Mariusz Wasik, Steffen Koschmieder, Tony R. Green, Radek C. Skoda and Tomasz Skorski

Article Information

PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 15, 2017
  • Accepted October 12, 2017
  • Published online October 17, 2017.


Contributors 
  • Margaret Nieborowska-Skorska, 1 Temple University School of Medicine, Department of Microbiology and Immunology and Fels Institute for Cancer Research & Molecular Biology, Philadelphia, PA, United States;
  • Silvia Maifrede, 1 Temple University School of Medicine, Department of Microbiology and Immunology and Fels Institute for Cancer Research & Molecular Biology, Philadelphia, PA, United States;
  • Yashodhara Dasgupta, 1 Temple University School of Medicine, Department of Microbiology and Immunology and Fels Institute for Cancer Research & Molecular Biology, Philadelphia, PA, United States;
  • Katherine Sullivan, 1 Temple University School of Medicine, Department of Microbiology and Immunology and Fels Institute for Cancer Research & Molecular Biology, Philadelphia, PA, United States;
  • Sylwia Flis, 2 National Medicines Institute, Department of Pharmacology, Warsaw, Poland;
  • Bac Viet Le, 3 Nencki Institute of Experimental Biology, Laboratory of Cytometry, Warsaw, Poland;
  • Martyna Solecka, 1 Temple University School of Medicine, Department of Microbiology and Immunology and Fels Institute for Cancer Research & Molecular Biology, Philadelphia, PA, United States;
  • Elizaveta A. Belyaeva, 4 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States;
  • Lucia Kubovcakova, 5 University Hospital Basel and University of Basel, Department of Biomedicine, Basel, Switzerland;
  • Morgan Nawrocki, 1 Temple University School of Medicine, Department of Microbiology and Immunology and Fels Institute for Cancer Research & Molecular Biology, Philadelphia, PA, United States;
  • Martin Kirschner, 6 RWTH Aachen University, Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Aachen, Germany;
  • Huaqing Zhao, 7 Temple University Lewis Katz School of Medicine, Department of Clinical Sciences, Philadelphia, PA, United States;
  • Josef T. Prchal, 8 University of Utah School of Medicine, Salt Lake City, UT, United States;
  • Katarzyna Piwocka, 3 Nencki Institute of Experimental Biology, Laboratory of Cytometry, Warsaw, Poland;
  • Alison R. Moliterno, 9 Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States;
  • Mariusz Wasik, 4 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States;
  • Steffen Koschmieder, 6 RWTH Aachen University, Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Aachen, Germany;
  • Tony R. Green, 10 Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom
  • Radek C. Skoda, 5 University Hospital Basel and University of Basel, Department of Biomedicine, Basel, Switzerland;
  • Tomasz Skorski, 1 Temple University School of Medicine, Department of Microbiology and Immunology and Fels Institute for Cancer Research & Molecular Biology, Philadelphia, PA, United States;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output